BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE)-- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and ...
BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE)-- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and ...
A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
Raludotatug deruxtecan (R-DXd) received FDA breakthrough therapy designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Phase 1 study demonstrated a ...
Promising signs of efficacy were observed in patients with heavily pretreated platinum-resistant high-grade serous ovarian cancer (HGSOC) without CDH6 pre-selection PRINCETON, N.J., June 2, 2025 ...
(RTTNews) - NextCure, Inc. (NXTC), announced Monday a strategic partnership with Simcere Zaiming to develop SIM0505, a novel antibody-drug conjugate or ADC targeting CDH6 or cadherin-6 for the ...
Oncusp Therapeutics Inc. has received IND clearance from the FDA to begin clinical trials with CUSP-06, a cadherin-6 (CDH6)-targeting antibody-drug conjugate designed for the treatment of multiple ...
Everolimus and aromatase inhibitors for advanced and recurrent low-grade serous ovarian carcinoma. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results